Faron Pharmaceuticals: Blood cancer study BEXMAB in full swing
Faron has prepared for increased bexmarilimab production and accelerated its BEXMAB study, which resulted in higher R&D costs and a weaker result than we expected. Our estimate changes are marginal, as we recently updated our assessment of the progress of the drug development program. The valuation picture remains unchanged compared to our assessment in January, as there have been no major changes in the timing or financial outlook of the studies.
Login required
This content is only available for logged in users
Faron Pharmaceuticals
Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.
Read more on company pageKey Estimate Figures06.03.2023
| 2022 | 23e | 24e | |
|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 |
| growth-% | |||
| EBIT (adj.) | -27.4 | -15.8 | -3.1 |
| EBIT-% (adj.) | -685,650.00 % | -394,522.50 % | -76,864.00 % |
| EPS (adj.) | -0.48 | -0.25 | -0.05 |
| Dividend | 0.00 | 0.00 | 0.00 |
| Dividend % | |||
| P/E (adj.) | - | - | - |
| EV/EBITDA | - | - | - |
